Expertise Partners
LIDE
LIDEÂ is an award-winning oncology contract research organization with 12 years of delivering drug evaluation services to 200+ clients worldwide. We offer traditional preclinical CRO services like pharmacology, PK, and biomarker studies with 70+ CDX models and 2000 patient-derived xenograft (PDX) models. Our library covers 50+ cancer types and 200+ models harbor special naturally-occurred drug-resistant and/or genetic alterations. Ask us about our proprietary tools for in-vivo drug validation in 7-10 days.
GemPharmatech
GemPharmatech Co., Ltd. is a leading company in China to provide high-quality animal model resources and services for biomedical community as well as pharmaceutical companies. Based on more than 16 years’ practice in laboratory animals of the former entity, GemPharmatech has the vision and is striving to become one of the best one-stop service center for production, distribution, and phenotyping of gene-modified mouse models for partners all across the world.
Certis
Certis Oncology Solutions is a life science technology company committed to realizing the promise of precision oncology. Our product is Certis Oncology Intelligence® — highly predictive therapeutic response data derived from advanced biological models of cancer and enhanced with AI-driven bioinformatics. Our functional platform informs individual treatment and drug development decisions. Certis incorporates both 3D cell-based assays and in silico models to accelerate the development of new cancer therapies and reduce the number of animal models.
XenoSTART
XenoSTART is a global nonclinical oncology contract research organisation focused on the development and utilisation of patient-derived xenograft models. Founded in 2007, XenoSTART was created in close collaboration with The START Center, an international cancer treatment and research organisation. This partnership provides the unique ability to generate clinically-relevant XenoSTART patient-derived xenograft (XPDX) models.
Our XPDX models are clinically annotated and include patient treatment history and outcome and are characterised through genomic profiling, histologic analysis, and in vivo drug sensitivity to relevant standards of care
Innovation Partner
Labcorp
Labcorp is a global leader of innovative and comprehensive laboratory services on a mission to improve health and improve lives. With more than 10,000 studies completed, 300+ human xenografts, 50+ mouse syngeneic and 400+ PDX models, we have amassed extensive experience and deep insights to inform your discovery oncology research. Our in vitro and in vivo pharmacology efficacy models, in vivo imaging technologies, ex vivo assessments and focal radiation capabilities provide the decision-driving data you need to advance drug candidates toward the next cancer research breakthrough.
Program Partner
DRL
We are a clinical research organization, which provides a variety of well-characterized biomaterials for pharmaceutical companies and research organizations, including tissue samples, cell lines, and 3D models of the tumor. We offer flexible customizable solutions for clinical and preclinical studies to reduce the costs of drug discovery.
Exhibition Partners
Studylog
Studylog's Animal Study Workflow Software® is designed for biomedical animal research and provides features for the design, planning, execution, analysis, and reporting of animal studies in a standardized, highly efficient manner, while protecting data integrity. Reducing many labs’ study-related labor by half, Studylog automates and streamlines the entire animal study process, making it easier, faster and cheaper, so researchers have more time and resources to get their job done.
Reaction Biology
Reaction Biology brings over 20 years of experience supporting the development of new small molecules and large molecule therapies. We offer a broad portfolio of services that can provide end-to-end solutions for drug discovery, combined with an agile science-focused culture that delivers the same high quality of data for projects of any size.
Champions Oncology
At Champions Oncology, we are passionate about aiding the pharmaceutical industry in developing the innovative treatments of today and the cures for tomorrow. We provide end-to-end research and development solutions throughout the drug development lifecycle. From screens using commercially-available and custom cell lines, to studies leveraging syngeneic or traditional patientderived studies xenograft (PDX) models, and modeling treatment response in the clinic, Champions Oncology is your partner in meeting today’s needs and innovating for tomorrow’s challenges.
